A drugmaker with one of the world's top-selling drugs Regeneron (NASDAQ: REGN) is a well-established biotech company that generates consistent revenue and profits. However, the drugmaker ...

Regeneron has more growth opportunities ahead ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Investor model based on the published ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a ...

Three stocks which have generated 100-bagger returns for investors over the past 20 years are Booking Holdings (NASDAQ: BKNG), Apple (NASDAQ: AAPL), and Regeneron Pharmaceuticals (NASDAQ: REGN).

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like ...